What Is FOXO4-DRI? Research Evidence & Profile

What Is FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI)?

FOXO4-DRI is a D-retro-inverso peptide associated with published FOXO4–p53 interaction research. This page identifies the material as Forkhead Box O4 D-Retro-Inverso Peptide (FOXO4-DRI). The FOXO4-DRI identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

0ClinicalTrials.gov query records

20PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for FOXO4-DRI is organized around FOXO4–p53 interaction studies, protein-interaction research, D-retro-inverso peptide characterization, and analytical peptide workflows. For FOXO4-DRI, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression.

Circulation · 2023 Feb 21

PMID 36515093

Selected PubMed record

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.

Nature communications · 2025 Jul 1

PMID 40593617

Selected PubMed record

FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.

Journal of cellular and molecular medicine · 2022 Jun

PMID 35510614

Selected PubMed record

FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice.

Naunyn-Schmiedeberg's archives of pharmacology · 2023 Oct

PMID 37074394

Selected PubMed record

FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.

Aging · 2020 Jan 20

PMID 31959736

Selected PubMed record

FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.

Frontiers in bioengineering and biotechnology · 2025

PMID 41625068

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Forkhead Box O4 D-Retro-Inverso Peptide (FOXO4-DRI)
Available Specifications: 10mg
Pack Format: 10 Vials

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI) Research Summary

Identity

Forkhead Box O4 D-Retro-Inverso Peptide (FOXO4-DRI); specifications: 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

0 registry records and 20 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI) is represented here by the catalogue identity Forkhead Box O4 D-Retro-Inverso Peptide (FOXO4-DRI). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for FOXO4-DRI is organized around FOXO4–p53 interaction studies, protein-interaction research, D-retro-inverso peptide characterization, and analytical peptide workflows. For FOXO4-DRI, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 20 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI) FAQ

What is FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI)?

What research records are indexed for FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI)?

The synchronized query returned 0 ClinicalTrials.gov records and 20 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is FOXO4 D-Retro-Inverso Peptide (FOXO4-DRI) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.